Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

被引：4
作者：
Ansari, Jawaher [1 ]
Hussain, Syed A. [2 ]
Ansari, Asif [3 ]
Glaholm, John [4 ]
机构：
[1] Beatson West Scotland Canc Ctr, 1053 Great Western Rd, Glasgow G12 0YN, Lanark, Scotland
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England
来源：
BIOLOGICS-TARGETS & THERAPY | 2013年 / 7卷
关键词：
metastatic RCC; vascular endothelial growth factor receptor inhibitor; molecular targeted agent; clear-cell carcinoma;
D O I：
10.2147/BTT.S25862
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
引用
收藏
页码：39 / 46
页数：8
相关论文
共 28 条
[1]   Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study [J].
Calvo, E. ;
Escudier, B. ;
Motzer, R. J. ;
Oudard, S. ;
Hutson, T. E. ;
Porta, C. ;
Bracarda, S. ;
Gruenwald, V. ;
Thompson, J. A. ;
Ravaud, A. ;
Kim, D. ;
Panneerselvam, A. ;
Anak, O. ;
Figlin, R. A. .
EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) :333-339
[2]   Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC). [J].
Cella, D. ;
Escudier, B. ;
Rini, B. I. ;
Chen, C. ;
Bhattacharyya, H. ;
Tarazi, J. C. ;
Rosbrook, B. ;
Kim, S. ;
Motzer, R. J. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3]  
Choueiri TK, 2008, CURR OPIN INVEST DR, V9, P658
[4]  
Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO
[5]  
2-#
[6]  
DUTCHER JP, 2008, J CLIN ONCOL S, V26
[7]   Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].
Escudier, Bernard ;
Pluzanska, Anna ;
Koralewski, Piotr ;
Ravaud, Alain ;
Bracarda, Sergio ;
Szczylik, Cezary ;
Chevreau, Christine ;
Filipek, Marek ;
Melichar, Bohuslav ;
Bajetta, Emilio ;
Gorbunova, Vera ;
Bay, Jacques-Olivier ;
Bodrogi, Istvan ;
Jagiello-Gruszfeld, Agnieszka ;
Moore, Nicola .
LANCET, 2007, 370 (9605) :2103-2111
[8]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150
[9]   Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J].
Escudier, Bernard ;
Eisen, Tim ;
Stadler, Walter M. ;
Szczylik, Cezary ;
Oudard, Stephane ;
Staehler, Michael ;
Negrier, Sylvie ;
Chevreau, Christine ;
Desai, Apurva A. ;
Rolland, Frederic ;
Demkow, Tomasz ;
Hutson, Thomas E. ;
Gore, Martin ;
Anderson, Sibyl ;
Hofilena, Gloria ;
Shan, Minghua ;
Pena, Carol ;
Lathia, Chetan ;
Bukowski, Ronald M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3312-3318
[10]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
123